Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.
Videos
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Blood and Breast Cancer News
2
Dr Hans Lee on the Game-Changing Myeloma Research from ASH 2025
3
Phase 3 Trial of Olverembatinib Cleared By FDA, EMA in Ph+ALL
4
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
5
